Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Maria Del Carmen
Maria Del Carmen Acosta Boj, Alicante ES
| Patent application number | Description | Published |
|---|---|---|
| 20100286230 | MODULATION OF TRPV EXPRESSION LEVELS - The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy. | 11-11-2010 |
Maria Del Carmen Banuls Polo, Valencia ES
Maria Del Carmen Cabrera Reyes, Mexico City MX
| Patent application number | Description | Published |
|---|---|---|
| 20100193401 | Ionic Liquid Catalyst for Improvement of Heavy and Extra Heavy Crude - The present invention relates to improving heavy crude oil, and extra through a scheme considering the use of ionic liquids catalysts based on Mo and Fe catalyst is highly miscible with crude oil and are in the homogeneous phase crude oil. | 08-05-2010 |
Maria Del Carmen Cajarville Basaistegui, Montevideo UY
Maria Del Carmen De Lucas Collantes, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20110165264 | USE OF CILASTATIN TO REDUCE NEPHROTATOXICITY OF VARIOUS COMPOUNDS - Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects. | 07-07-2011 |
Maria Del Carmen Martinez Guerrero, Mexico City MX
| Patent application number | Description | Published |
|---|---|---|
| 20100025303 | Application of microporous carbon adsorbent for reducing the benzene content in hydrocarbon streams - The present invention is related with the application of an adsorbent material of microporous carbon (MCA), prepared from the direct pyrolysis of copolymers generically known as Saran, in adsorption processes to reduce the benzene content in naphtha boiling range hydrocarbon streams, between 27 and 191° C., in which is preferable to perform a first separation by distillation of the C6's fraction, and a further separation of Benzene by adsorption through an adsorbent material bed, obtaining the fraction of C6's free of Benzene and an adsorbent with Benzene, which is further regenerated by pressure or temperature swing desorption or by displacement using a desorbent such as an inert gas at high temperature or by passing a desorbent which after the process, the desorbent and Benzene are separated by distillation. The fraction of C6's free of Benzene is reintegrated to the hydrocarbon stream and providing a gasoline with a Benzene content less than 1 volume %. Besides, the application of the MCA in this type of process allows obtaining Benzene with a minimum purity of 99.8 weight % and a maximum toluene content of 0.1 weight %, satisfying the specifications of ASTM D-2359-02 for Refined Benzene-535 | 02-04-2010 |
Maria Del Carmen Masdeu Margalef, Barcelona ES
| Patent application number | Description | Published |
|---|---|---|
| 20090029996 | Pyridazin-3(2H)-One Derivatives And Their Use As Pde4 Inhibitors - The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention and suppression of related pathological conditions, diseases and disorders, in particular asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, topic dermatitis, psoriasis or irritable bowel disease. | 01-29-2009 |
Maria Del Carmen Ramos Martín, Armilla-Granada ES
| Patent application number | Description | Published |
|---|---|---|
| 20110319484 | NEUROPROTECTIVE COMPOUNDS - The invention describes the use of (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl-1-naphthalenyl propanoate derivatives, optionally mono- or di-methylated at the carbon in the alpha position of propanoic acid, of formula (I), where R is CH | 12-29-2011 |
Maria Del Carmen Rotger Pons, Palma De Mallorca ES
| Patent application number | Description | Published |
|---|---|---|
| 20110294772 | USE OF CYCLOSQUARAMIDE COMPOUNDS AS ANTI-TUMOUR AGENTS - Use of squaramide-based macrocylic compounds as kinase inhibitor agents and as anti-tumour agents. More specifically, said compounds are used to treat diseases such as cancer, diabetes, neurodegenerative diseases, HIV replication, etc. Furthermore, the present invention likewise relates to pharmaceutical compositions that contain said compounds | 12-01-2011 |
Maria Del Carmen Serra Comas, Esplugues De Llobregat (barcelona) ES
| Patent application number | Description | Published |
|---|---|---|
| 20110207769 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER - The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders | 08-25-2011 |
Maria Del Carmen Serra Comas, L'Hospitalet De Llobregat ES
| Patent application number | Description | Published |
|---|---|---|
| 20100075984 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY - Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(═O)— or —NHC(═S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical of a cycle; R4 represents —H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent —H or halogen, and R7 represents —H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans. | 03-25-2010 |
Maria Del Carmen Vall Pares, Barcelona ES
| Patent application number | Description | Published |
|---|---|---|
| 20090324717 | Extended release pharmaceutical formulation of metoprolol and process for its preparation - The invention provides an extended release coated granule comprising a granule having a particle size ranging from 0.2 to 2 mm, a friability lower than or equal to 1% and comprising metoprolol succinate as active ingredient in an amount ranging from 10 to 75% by weight of the granule and at least one binder selected from microcrystalline cellulose and methylcellulose, coated with a film-former coating agent. It also provides a process for the preparation of said extended release coated granules, as well as pharmaceutical formulations containing them. | 12-31-2009 |
Maria Del Carmen Velazquez Pereda, Sao Paulo -Sp BR
| Patent application number | Description | Published |
|---|---|---|
| 20110251415 | XYLITOL ESTERS AND ETHERS APPLIED AS ALTERNATIVE EMULSIFIERS, SOLVENTS, CO-EMULSIFIERS AND PRESERVATIVE SYSTEMS FOR PHARMACEUTICAL AND COSMETIC PRODUCTS - This patent application has as purpose the application/utilization of esters and ethers derived from xylitol, obtained by organic synthesis, as alternative emollient, moisturizing, emulsifier and co-emulsifier and preservatives for pharmaceutical, cosmetic and veterinarian products. The molecules required in this invention patent are mainly xylitol esters and ethers associated to the chains of fatty acids and alcohols (FIGS. | 10-13-2011 |